2023-2030 年全球自动乳腺超声机 (ABUS) 市场

市场概览

全球自动化乳腺超声机市场规模将在 2023 年达到 14.24 亿美元，到 2030 年达到 24.52 亿美元，在预测期内（2023-2030 年）以 12.4% 的复合年增长率增长。据预测，

一种更常见的技术，自动乳腺超声 (ABUS)，可能是乳腺组织緻密（腺体和纤维比脂肪更多）的女性唯一的额外危险因素。它可以多检测出多达 30% 的肿瘤。 乳房緻密的女性可能会发现乳房 X 光检查不足，而 ABUS 可以检测出更多的恶性肿瘤。 ABUS 在超声期间不使用电离辐射，是一种快速、无痛且有效的緻密乳房成像方法。

市场动态

推动全球自动乳腺超声机市场的关键因素 随着自动乳腺超声机技术的进步和对乳腺癌的认识不断提高，政府的举措有利于全球乳腺癌发病率的上升，这是市场的最大推动力。

全球乳腺癌患病率上升已成为市场最重要的驱动力。

据世界卫生组织称，乳腺癌起源于乳房腺体组织的导管 (85%) 或小叶 (15%) 的活细胞（上皮细胞）。 恶性转化最初局限于导管或小叶，通常无症状，转移风险低。 到 2020 年，乳腺癌将导致全球 684,000 人死亡，影响 230 万女性。 截至 2020 年底，乳腺癌是世界上最常见的癌症，过去五年有 780 万女性被确诊。 乳腺癌是导致全球女性伤残调整生命年 (DALYs) 损失最多的癌症类型。 乳腺癌发生在世界所有国家青春期后的任何年龄的女性身上，但在以后的生活中更为常见。

据美国癌症协会估计，到 2022 年，将有大约 287,840 例新的女性浸润性乳腺癌病例、大约 51,400 例新的乳腺癌 (DCIS) 病例以及大约 43,250 例与乳腺癌相关的女性死亡病例。我希望它能成为一个例子。 乳腺癌最常见于中年和老年妇女。 乳腺癌诊断的典型年龄是 62 岁。 因此，女性发现乳腺癌的平均年龄为 62 岁或更小。 乳腺癌在 45 岁以下的女性中极为罕见。

自动乳腺超声机的高价格阻碍了市场增长。

自动乳腺超声成像系统的应用受到许多国家/地区严格法规的限制。 此外，与传统癌症筛查方法相比，自动乳腺超声系统 (ABUS) 的高成本预计将抑制市场扩张。

COVID-19 影响分析

一旦 COVID-19 大流行开始，感染频率的严重程度和传播速度都会增加。 在全球大流行初期，感染 COVID-19 病毒的患者人数有所增加。 为了减少和控制不同的传播途径，医院已将应急方案作为重中之重。 因此，需要超声筛查的择期手术已经减少。 儘管选择性超声治疗有所下降，但在需要成像服务的紧急程序中使用 X 射线、CT 扫描和超声的情况有所增加。 由于 COVID-19 的长期影响，预计超声诊断设备的引入将增加用于专业诊断，尤其是在肾臟和肺部。 在大流行早期，肺部超声扫描显示出增加的趋势。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

• 市场影响因素
  • 司机
    • 增加自动乳腺超声设备的技术进步
    • 提高对乳腺癌的认识和政府举措
  • 约束因素
    • 自动乳腺超声系统的价格更高
  • 机会
  • 影响分析

第五章行业分析

• 波特的五力分析
• 供应链分析
• 定价分析
• 监管分析

第 6 章 COVID-19 分析

• COVID-19 市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章按超声类型分类

• 多普勒超声
• 彩色多普勒
• 经阴道超声

第八章应用

• 乳房成像
• 放映

第 9 章最终用户

• 医院
• 影像诊断中心
• 诊断实验室

第10章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第11章竞争格局

• 主要发展和战略
• 公司股票分析
• 产品基准
• 值得关注的主要公司名单

第12章公司简介

• General Healthcare Company
  • 公司简介
  • 产品组合和说明
  • 主要亮点
  • 财务摘要
• Hitachi, Ltd
• Koninklijke Philips N.V.
• Siemens AG
• SonoCine Inc
• Qview Medical
• Koios Medical
• Volpara Solutions Limited
• Delphinus Medical Technologies, Inc.
• Nova Medical Inc

第13章 DataM

Market Overview

The global automated breast ultrasound systems market size was valued at US$ 14,24 million in 2023 and is estimated to reach US$ 2452 million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).

A more popular technique, Automated Breast Ultrasound (ABUS), can detect up to 30% more tumors in women with dense breast tissue (more glandular or fibrous than fatty), even if it is the only extra risk factor. Women with denser breasts may make mammography insufficient and can employ ABUS to discover more malignancies. No ionizing radiation is used during ultrasound procedures, and ABUS is a quick, painless, and efficient approach to photographing dense breasts.

Market Dynamics

The major factors driving the global Automated breast ultrasound systems market rising prevalence of breast cancer worldwide is the most significant driving factor of the market, as increasing technological advancements in automated breast ultrasound systems and rising awareness regarding breast cancer favorable government initiatives.

The rising prevalence of breast cancer worldwide is the most significant driving factor in the market.

According to WHO, in the glandular tissue of the breast, breast cancer begins in the living cells (epithelium) of the ducts (85%) or lobules (15%). The malignant development is initially restricted to the duct or lobule, where it often exhibits no symptoms and has a low risk of spreading. 684,000 people worldwide died in 2020 due to breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, diagnosed in 7.8 million women in the previous five years. Breast cancer is the form of cancer that results in the most lost disability-adjusted life years (DALYs) for women globally. Breast cancer occurs in every nation of the world in women at any age after puberty but with rising rates in later life.

The American Cancer Society predicts that in 2022, there will be about 287,840 new cases of invasive breast cancer in women, about 51,400 new instances of ductal carcinoma in situ (DCIS), and about 43,250 new cases of breast cancer-related deaths in women. Breast cancer is more common in women in their middle years and older. The typical age at breast cancer diagnosis is 62 years old. The average age at which breast cancer in women is found is therefore 62 years of age or less. Breast cancer diagnoses in women under 45 are incredibly uncommon.

The automated breast ultrasound system's high price will hamper the market's growth.

The application of automated breast ultrasound imaging systems has been constrained by severe rules in a number of nations. Additionally, the high cost of automated breast ultrasound systems (ABUS) compared to traditional cancer screening methods is anticipated to restrain market expansion.

COVID-19 Impact Analysis

Infectious disease frequency increased in terms of the severity and rate of dissemination with the beginning of the COVID-19 pandemic. During the early stages of the global pandemic, the number of patients infected with the COVID-19 virus increased. To decrease and control different infection transmission, hospitals adopted emergency protocols as a top priority. This led to a decline in elective procedures that needed ultrasound screening. The use of X-rays, CT scans, and ultrasounds for emergency procedures that needed imaging services increased despite a reduction in elective ultrasound treatments. The adoption of ultrasound equipment for specialized diagnostics, notably for kidneys and lungs, is anticipated to increase due to COVID-19's long-term effects. The number of ultrasound operations for lungs exhibited a rising trend during the early stages of the pandemic.

Segment Analysis

The hospital's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ABUS implementation is progressively gaining momentum in more hospitals to meet the patients' diagnostic demands. The demand for ABUS in these healthcare settings will be driven by rising cancer screening test usage among young and middle-aged women. Hospitals are installing ABUS to provide safer diagnostic choices because pregnant women cannot get mammography due to the radiation danger.

Breast cancer surgery involves operating to remove the tumor, which is a crucial part of treatment for the disease. Breast cancer surgery can be used either on its own or in conjunction with other therapies, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy, administered in a hospital setting under the guidance of a qualified doctor.

Each year, more than 100,000 American women get a mastectomy. Although it is frequently done to treat breast cancer, it is occasionally done to lower the chance of developing breast cancer. Because procedures must be performed in hospitals under the supervision of doctors, the hospital sector drives the market. Compared to general or specialty hospitals, teaching hospitals in several affluent nations have seen a dramatic increase in demand for various treatment modalities. However, the number of new hospitals in developing nations in North America has sharply increased. Imaging modalities typically have their room in new hospitals. Rising competition and rising demand for top-notch medical care are the two main reasons predicted to drive segment expansion.

Geographical Analysis

North America holds the largest market share in the global automated breast ultrasound systems market.

According to the American Society of Cancer, about 281,550 new breast cancer cases will be discovered in women in 2021, and 43,600 women will pass away from the disease. The prevalence of breast cancer is rising, increasing the need for cutting-edge breast imaging equipment and support for efficient therapies. The ABUS market in the U.S. will grow as government campaigns to inform and educate women about breast cancer and the value of screening increase. According to the Breast Cancer Organization, 1 in 8 (or around 13%) American women will eventually develop invasive breast cancer.

In the United States, women are anticipated to receive diagnoses for 287,840 new instances of invasive breast cancer and 51,500 new cases of non-invasive (in situ) breast cancer in 2022. In 2022, it's anticipated that 2,710 new instances of invasive breast cancer will be found in men. About 1 in 833 men may develop breast cancer in their lives. In the U.S., more than 3.8 million women have had breast cancer in the past as of January 2022. Women who have completed treatment and those who are presently receiving it are included. Several foundations in the United States have launched awareness programs, including the Susan Komen Foundation, the National Breast Cancer Foundation, and the American Society of Cancer's National Breast Cancer Awareness (NBCA) month. These will benefit the need for automated breast ultrasonography systems for detecting breast cancer in breast tissue with dense cellularity.

Competitive Landscape

The Automated breast ultrasound systems market is moderately competitive with local and global companies' presence GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG , SonoCine Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, Koios DS, a software platform powered by artificial intelligence (AI) and shown to effectively diagnose thyroid and breast malignancies in ultrasound tests, has received CE Marking under the EU MDR, according to Koios Medical, a pioneer in the field of cancer diagnostics using ultrasound. The innovative dual-diagnosis method, developed utilizing data from a global network of 55 sites, speeds up interpretation, automates reporting, and shortens the time it takes to administer medication while eliminating unnecessary surgery

General Electric Company.

Overview: E Healthcare, a division of General Electric Company, is a global provider of medical devices that creates, develops, produces, and sells diagnostic imaging and clinical systems, as well as a variety of healthcare IT solutions, products and services for drug discovery, biopharmaceutical production, and cellular technologies. Additionally, GE Healthcare offers services including computerized data management, remote diagnostic and repair services for medical equipment made by the business and others, performance enhancement and performance solutions services, and other services.

Product Portfolio:

Invenia ABUS 2.0: One of the biggest widespread risk factors for getting breast cancer is having thick breasts, which affects about 40% of women. The clinical data supporting the use of ultrasonography to detect tiny, node-negative, invasive tumors that mammography misses is emerging. For dense breast imaging in the screening context, Invenia ABUS 2.0 supplemental imaging is designed.

The global automated breast ultrasound systems market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing technological advancements in automated breast ultrasound systems
    • 4.1.1.2. Rising awareness regarding breast cancer and favorable government initiatives
  • 4.1.2. Restraints:
    • 4.1.2.1. The automated breast ultrasound system's high price
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1 Porter's Five Forces Analysis
• 5.2 Supply Chain Analysis
• 5.3 Pricing Analysis
• 5.4 Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Ultrasound Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 7.1.2. Market Attractiveness Index, By Ultrasound Type
• 7.2. Doppler ultrasound
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Color Doppler
• 7.4. Transvaginal ultrasound

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Breast imaging
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Screening

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostic Imaging Centers
• 9.4. Diagnostic Laboratories

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Products Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. General Healthcare Company
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Hitachi, Ltd
• 12.3. Koninklijke Philips N.V.
• 12.4. Siemens AG
• 12.5. SonoCine Inc
• 12.6. Qview Medical
• 12.7. Koios Medical
• 12.8. Volpara Solutions Limited
• 12.9. Delphinus Medical Technologies, Inc.
• 12.10. Nova Medical Inc

LIST NOT EXHAUSTIVE

13. Global Automated breast ultrasound systems Market - DataM

• 13.1. Appendix
• 13.2. About Us and Application
• 13.3. Contact Us